Study details
Enrolling now
A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)
Turn Therapeutics
NCT IDNCT07355075ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 12 months
Ages
18–70
Locations
1 site in TX
About this study
This trial is testing a new treatment, GX-03, for moderate to severe eczema. Participants will apply GX-03 or a vehicle control on their skin for 8 weeks and doctors will measure how well the treatment works using several methods. The study will also monitor any side effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take GX-03
- 2.Vehicle
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Change in NRS Max Itch
Body systems
Dermatology